Abstract:BACKGROUND: Programmed death ligand 1 (PD-L1) has been demonstrated to facilitate tumor progression and therapeutic resistance in an immune-independent manner. Nevertheless, the function and underlying signaling network(s) of cancer cell-intrinsic PD-L1 action remain largely unknown. Herein, we sought to better understand how ubiquitin-specific peptidase 51 (USP51)/PD-L1/integrin beta-1 (ITGB1) signaling performs a cell-intrinsic role in mediating chemotherapeutic resistance in non-small cell lung cancer (NSCLC).METHODS: Western blotting and flow cytometry were employed for PD-L1 detection in NSCLC cell lines. Coimmunoprecipitation and pulldown analyses, protein deubiquitination assay, tissue microarray, bioinformatic analysis and molecular biology methods were then used to determine the significance of PD-L1 in NSCLC chemoresistance and associated signaling pathways in several different cell lines, mouse models and patient tissue samples. Ubiquitin-7-amido-4-methylcoumarin (Ub-AMC)-based deubiquitinase activity, cellular thermal shift and surface plasmon resonance (SPR) analyses were performed to investigate the activity of USP51 inhibitors.RESULTS: We provided evidence that cancer cell-intrinsic PD-L1 conferred the development of chemoresistance by directly binding to its membrane-bound receptor ITGB1 in NSCLC. At the molecular level, PD-L1/ITGB1 interaction subsequently activated the nuclear factor-kappa B (NF-κB) axis to elicit poor response to chemotherapy. We further determined USP51 as a bona fide deubiquitinase that targeted the deubiquitination and stabilization of the PD-L1 protein in chemoresistant NSCLC cells. Clinically, we found a significant direct relationship between the USP51, PD-L1 and ITGB1 contents in NSCLC patients with chemoresistant potency. The elevated USP51, PD-L1 and ITGB1 levels were strongly associated with worse patient prognosis. Of note, we identified that a flavonoid compound dihydromyricetin (DHM) acted as a potential USP51 inhibitor and rendered NSCLC cells more sensitive to chemotherapy by targeting USP51-dependent PD-L1 ubiquitination and degradation in vitro and in vivo.CONCLUSIONS: Together, our results demonstrated that the USP51/PD-L1/ITGB1 network potentially contributes to the malignant progression and therapeutic resistance in NSCLC. This knowledge is beneficial to the future design of advanced cancer therapy.

Interaction Between Cd147 And P-Glycoprotein And Their Regulation By Ubiquitination In Breast Cancer Cells

Involvement of CD147 in Regulation of Multidrug Resistance to P‐gp Substrate Drugs and in Vitro Invasion in Breast Cancer Cells

Up‐regulation of CD147 and Matrix Metalloproteinase‐2, ‐9 Induced by P‐glycoprotein Substrates in Multidrug Resistant Breast Cancer Cells

Overexpression of ubiquitin carboxyl terminal hydrolase-L1 enhances multidrug resistance and invasion/metastasis in breast cancer by activating the MAPK/Erk signaling pathway.

Uch-L1 Involved in Regulating the Degradation of Egfr and Promoting Malignant Properties in Drug-Resistant Breast Cancer

Regulation of the Stability of P-Glycoprotein by Ubiquitination

[CD147 and Matrix Metallo-Proteinase (MMP) 2 and MMP9 Expression in Multidrug Resistant Breast Cancer Cells Treated with P-glycoprotein Substrate Drugs].

Modulation of CD147-induced matrix metalloproteinase activity: role of CD147 N-glycosylation.

Relationship Between the Expression of P-gp and that of CD147, MMPs in None Small Cell Lung Cancer

A Regulatory Network Analysis of the Importance of USP15 in Breast Cancer Metastasis and Prognosis

Proteome Analysis of Multidrug Resistance of Human Oral Squamous Carcinoma Cells Using Cd147 Silencing

The role of P-glycoprotein/cellular prion protein interaction in multidrug-resistant breast cancer cells treated with paclitaxel

F-Box Protein Fbxo22 Mediates Polyubiquitination and Degradation of Cd147 to Reverse Cisplatin Resistance of Tumor Cells

Recent advances on the intervention sites targeting USP7-MDM2-p53 in cancer therapy

USP51/PD‐L1/ITGB1‐deployed juxtacrine interaction plays a cell‐intrinsic role in promoting chemoresistant phenotypes in non‐small cell lung cancer

EGFR/HER2 inhibitors effectively reduce the malignant potential of MDR breast cancer evoked by P-gp substrates in vitro and in vivo.

Deglycosylation of CD147 down-regulates Matrix Metalloproteinase-11 expression and the adhesive capability of murine hepatocarcinoma cell HcaF in vitro.

Extracellular matrix metalloproteinase inducer (CD147/BSG/EMMPRIN)-induced radioresistance in cervical cancer by regulating the percentage of the cells in the G2/m phase of the cell cycle and the repair of DNA Double-strand Breaks (DSBs).

Involvement Of Egfr In The Promotion Of Malignant Properties In Multidrug Resistant Breast Cancer Cells

Ubiquitin carboxyl-terminal hydrolases: involvement in cancer progression and clinical implications

N-linked Glycosylation at Asn152 on CD147 Affects Protein Folding and Stability: Promoting Tumour Metastasis in Hepatocellular Carcinoma